Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Mirum Pharmaceuticals rallied after strong Q2 revenue tied to LIVMARLI and its bile acid portfolio, expansion into new rare-disease patients, and an upgraded full-year outlook. Investors are awaiting the Sept. 26 FDA decision on zilurgisertib, and leadership was granted new stock options.
Incyte’s (INCY) shares rose for the week while Mirum Pharmaceuticals (MIRM) bounced, as investors look ahead to a Sept. 26 FDA decision on zilurgisertib for an ultra-rare bone disease.